Nusinersen for adults with spinal muscular atrophy.

Doruk ArslanBerin InanMuhammed KilincCan Ebru Bekircan-KurtSevim Erdem-OzdamarErsin Tan

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

Overall, 78% of patients have responded to treatment according to HFMSE or 6MWT. ALSFRS-R and 6MWT may be alternative tools to monitor nusinersen effect.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported